Tracey Carson-Johnson
Family · Henderson, NCNPI 1609467638
Payments from drug & device makers
Across 80 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$352
- Pfizer$211
- AbbVie$143
- Lilly USA, LLC$109
- Aimmune Therapeutics, Inc.$66
- AstraZeneca$66
- plus $434 from 19 others
What the payments were for
- Food & beverage$1,382100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $352 |
| Pfizer | 12 | $211 |
| AbbVie | 9 | $143 |
| Lilly USA, LLC | 6 | $109 |
| Aimmune Therapeutics, Inc. | 3 | $66 |
| AstraZeneca | 5 | $66 |
| GSK | 3 | $47 |
| Sanofi Pasteur Inc. | 2 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Teleflex LLC | 1 | $27 |
| Boston Scientific | 1 | $23 |
| Mylan Specialty L.p. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Bayer | 1 | $21 |
| Corcept Therapeutics | 1 | $21 |
| Seqirus USA Inc | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Dexcom, Inc. | 1 | $15 |
| Amgen | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Merck | 1 | $13 |
| Alkermes, Inc. | 1 | $11 |
How this compares
$1,382 in reported general payments places this provider in the 75th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 38 | $51,527 |
| OzempicSemaglutide | 45 | $44,619 |
| FarxigaDapagliflozin Propanediol | 31 | $29,588 |
| RybelsusSemaglutide | 14 | $18,180 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $16,884 |
| JardianceEmpagliflozin | 21 | $12,222 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $6,434 |
| EliquisApixaban | 11 | $5,932 |
| Varenicline Tartrate | 15 | $2,265 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $1,833 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 77 | $1,765 |
| Atorvastatin Calcium | 163 | $1,739 |
| Rosuvastatin Calcium | 91 | $1,123 |
| Gabapentin | 56 | $1,054 |
| Amlodipine Besylate | 127 | $760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $352 | $62,79959 claims |
| Lilly USA, LLCMounjaro | $109 | $51,52738 claims |
| AstraZenecaFarxiga | $66 | $29,58831 claims |
| GSKTrelegy Ellipta | $47 | $16,88412 claims |
| PfizerEliquis | $211 | $5,93211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,522 family providers in North Carolina.
Other family in Henderson
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.